191 related articles for article (PubMed ID: 38542198)
1. Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and Immortalized Cell Lines, and on
Uram Ł; Pieńkowska N; Misiorek M; Szymaszek Ż; Twardowska M; Siorek M; Wołowiec S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542198
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.
Uram Ł; Misiorek M; Pichla M; Filipowicz-Rachwał A; Markowicz J; Wołowiec S; Wałajtys-Rode E
Molecules; 2019 Oct; 24(20):. PubMed ID: 31652556
[TBL] [Abstract][Full Text] [Related]
3. Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines.
Uram Ł; Filipowicz A; Misiorek M; Pieńkowska N; Markowicz J; Wałajtys-Rode E; Wołowiec S
Eur J Pharm Sci; 2018 Nov; 124():1-9. PubMed ID: 30118847
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Uram Ł; Markowicz J; Misiorek M; Filipowicz-Rachwał A; Wołowiec S; Wałajtys-Rode E
Eur J Pharm Sci; 2020 Sep; 152():105439. PubMed ID: 32615261
[TBL] [Abstract][Full Text] [Related]
5. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.
Ramer R; Walther U; Borchert P; Laufer S; Linnebacher M; Hinz B
J Lipid Res; 2013 Nov; 54(11):3116-29. PubMed ID: 23943857
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Badawi AF; Eldeen MB; Liu Y; Ross EA; Badr MZ
Cancer Res; 2004 Feb; 64(3):1181-9. PubMed ID: 14871855
[TBL] [Abstract][Full Text] [Related]
7. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Mustafa A; Kruger WD
Clin Cancer Res; 2008 Aug; 14(15):4935-42. PubMed ID: 18676768
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Fulzele SV; Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2006 Mar; 58(3):327-36. PubMed ID: 16536899
[TBL] [Abstract][Full Text] [Related]
9. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration.
Kuipers GK; Slotman BJ; Wedekind LE; Stoter TR; Berg Jv; Sminia P; Lafleur MV
Int J Radiat Biol; 2007 Oct; 83(10):677-85. PubMed ID: 17729162
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
Kusunoki N; Yamazaki R; Kawai S
Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A₂ and peroxisome proliferator-activated receptor gamma.
Zhang M; Xu ZG; Shi Z; Shao D; Li O; Li W; Li ZJ; Wang KZ; Chen L
Mol Cell Biochem; 2011 Sep; 355(1-2):233-40. PubMed ID: 21559762
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
14. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis.
Liu NB; Peng T; Pan C; Yao YY; Shen B; Leng J
World J Gastroenterol; 2005 Oct; 11(40):6281-7. PubMed ID: 16419156
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Chu TH; Chan HH; Kuo HM; Liu LF; Hu TH; Sun CK; Kung ML; Lin SW; Wang EM; Ma YL; Cheng KH; Lai KH; Wen ZH; Hsu PI; Tai MH
Oncotarget; 2014 Mar; 5(6):1475-90. PubMed ID: 24721996
[TBL] [Abstract][Full Text] [Related]
18. Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/β-catenin signaling pathway.
Srivastava S; Dewangan J; Mishra S; Divakar A; Chaturvedi S; Wahajuddin M; Kumar S; Rath SK
Phytomedicine; 2021 Apr; 84():153484. PubMed ID: 33667839
[TBL] [Abstract][Full Text] [Related]
19. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.
Sareddy GR; Geeviman K; Ramulu C; Babu PP
J Neurooncol; 2012 Jan; 106(1):99-109. PubMed ID: 21847707
[TBL] [Abstract][Full Text] [Related]
20. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.
Zhang LJ; Wang SY; Huo XH; Zhu ZL; Chu JK; Ma JC; Cui DS; Gu P; Zhao ZR; Wang MW; Yu J
World J Gastroenterol; 2009 Jun; 15(22):2731-8. PubMed ID: 19522023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
